Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-11-07
2006-11-07
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S329000, C530S330000, C530S331000, C514S016700, C514S017400, C514S018700, C514S019300
Reexamination Certificate
active
07132392
ABSTRACT:
Disclosed are methods of inhibiting cell motility, for example, by inhibiting the binding between an intracellular transducer and a receptor protein tyrosine kinase, and more particularly by inhibiting hepatocyte growth factor (HGF) induced cell motility. The present invention also provides a method of inhibiting angiogenesis. The methods of the present invention employ peptides such as phosphotyrosyl mimetics. The present invention further provides methods of preventing and/or treating diseases, disorders, states, or conditions such as cancer, particularly metastatic cancer comprising administering to a mammal of interest one or more peptides of the present invention. Also disclosed are methods of blocking HGF, VEGF, or bFGF-stimulated migration, cell proliferation, and formation of capillary-like structures
REFERENCES:
patent: 3906031 (1975-09-01), Carpino et al.
patent: 4394519 (1983-07-01), Carpino et al.
patent: 4879398 (1989-11-01), Getman et al.
patent: 5182263 (1993-01-01), Danho et al.
patent: 5200546 (1993-04-01), Burke, Jr. et al.
patent: 5272268 (1993-12-01), Toyoda et al.
patent: 5296608 (1994-03-01), Danho et al.
patent: 5369110 (1994-11-01), Schmidlin et al.
patent: 5457114 (1995-10-01), Stüber et al.
patent: 5463062 (1995-10-01), Hemmerle et al.
patent: 5491253 (1996-02-01), Stuk et al.
patent: 5508437 (1996-04-01), Danho et al.
patent: 5525733 (1996-06-01), Novack et al.
patent: 5580979 (1996-12-01), Bachovchin
patent: 5587372 (1996-12-01), Aszodi et al.
patent: 5612370 (1997-03-01), Atwal
patent: 5616776 (1997-04-01), Stuk et al.
patent: 5627283 (1997-05-01), Stüber et al.
patent: 5646036 (1997-07-01), Schwall et al.
patent: 5679842 (1997-10-01), Kleiner
patent: 5686292 (1997-11-01), Schwall et al.
patent: 5688992 (1997-11-01), Burke, Jr. et al.
patent: 5698731 (1997-12-01), Bosetti et al.
patent: 5707624 (1998-01-01), Nickoloff et al.
patent: 5710129 (1998-01-01), Lynch et al.
patent: 5710173 (1998-01-01), Tang et al.
patent: 5712395 (1998-01-01), App et al.
patent: 5753687 (1998-05-01), Mjalli et al.
patent: 5756817 (1998-05-01), Choi et al.
patent: 5773411 (1998-06-01), Wells et al.
patent: 5780496 (1998-07-01), Tang et al.
patent: 5786454 (1998-07-01), Waksman et al.
patent: 5789427 (1998-08-01), Chen et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5843997 (1998-12-01), Heinz et al.
patent: 5849693 (1998-12-01), Wells et al.
patent: 5849742 (1998-12-01), App et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883110 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5886195 (1999-03-01), Tang et al.
patent: 5891917 (1999-04-01), Tang et al.
patent: 5912183 (1999-06-01), Comoglio et al.
patent: 5935993 (1999-08-01), Tang et al.
patent: 5958957 (1999-09-01), Andersen et al.
patent: 5965558 (1999-10-01), Mjalli et al.
patent: 5972978 (1999-10-01), Andersen et al.
patent: 5981569 (1999-11-01), App et al.
patent: 6037134 (2000-03-01), Margolis
patent: 6228986 (2001-05-01), Lanter et al.
patent: 6307090 (2001-10-01), Burke et al.
patent: WO 94/07913 (1994-04-01), None
patent: WO 95/11917 (1995-05-01), None
patent: WO 96/23813 (1996-08-01), None
patent: WO 97/08193 (1997-03-01), None
patent: WO 9708193 (1997-03-01), None
patent: WO 00/56760 (2000-09-01), None
patent: WO 00/73326 (2000-12-01), None
Yao Z-J, King CR, Cao, T, Kelley J, Milne GWA, Voight JH, Burke TR. Potent Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. J. Med. Chem. 1999, 42, 25-35.
RS Herbst. Int. J. Radiation Oncology Biol. Phys. (2004) 59, 21-26.
ML Janmaat and G Giaccone. The Oncologist (2003), 8, 576-586.
F-DT Lung and J-Y Tsai. Biopolymers (2003) 71, 132-140.
M Ranson. British J. Cancer (2004) 90, 2250-2255.
Falm Eskens. British J. Cancer (2004) 90, 1-7.
J Dancey. Int. J. Radiation Oncology Biol. Phys. (2004) 58, 1003-1007.
L Oligino, et al. J. Biol. Chem. (1997) 272, 29046-29052.
Y Gao, et al. J. Med. Chem. (2000) 43, 911-920.
B Gay, et al. Int. J. Cancer (1999) 83, 235-241.
P Furet, et al. J. Med. Chem. (1998) 41, 3442-3449.
Z-J Yao, et al. J. Med. Chem.(1999) 42, 25-35.
Webster's Online Dictionary. Accessed Oct. 1, 2004 at http://machaut.uchicago.edu/cgi-bin/WEBSTER.sh?WORD=oxalyl.
SIGMA. Designing Custom Peptides. http://www.sigma-genosys.com/peptide—design.asp (Accessed Dec. 16, 2004). 2 pages.
HJC Berendsen. A Glimpse of the Holy Grail? Science (1998) 282. 642-643.
D Voet and JG Voet. Biochemistry, 2nd Edition.(1995). 235-241.
DE Smilek, et al. A single amino acid . . . Proc. Natl. Acad. Sci. USA (1991) 88.9633-9637.
Z-J Yao, et al. J. Med. Chem. (1999) 42, 25-35.
HJC Berendsen. A Glimpse of the Holy Grail? Science (1998) 282. 642-643.
D Voet and JG Voet. Biochemistry, 2nd Edition.(1995). 235-241.
DE Smilek, et al. A single amino acid . . . Proc. Natl. Acad. Sci. USA (1991) 88. 9633-9637.
J. Rudinger. In: Peptide Hormones, JA Parsons, Ed. (1976) 1-7.
W.S. Messer, “Vasopressin and Oxytocin”, web document updated Apr. 3, 2000; http://www.neurosci.pharm.utoledo.edu/MBC3320/vasopressin.htm; 5 pages.
Ye et al., “L-O-(2-Malonyl)tyrosine” A New Phosphotyrosyl Mimetic for the Preparation of Src Homology 2 Domain Inhibitory Peptides, J. Med. Chem. vol. 38, pp. 4270-4275, 1995.
Burke, Jr., et al., “4′-O-[2-(2-Fluoromalonyl)]-L-tyrosine: A Phosphotyrosyl Mimic for the Preparation of Signal Transduction Inhibitory Peptides”, J. Med. Chem., vol. 39, pp. 1021-1027, Mar. 1, 1996.
Schoepfer et al., “Structure-based Design of Peptidomimetic Ligands of Grb2-SH2 Domain”, Bioorganic & Medicinal Chemistry Letters 8, pp. 2865-2870, 1998.
Yao et al., “Potent Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands”, J. Med. Chem., vol. 42, pp. 25-35, 1999.
Gay et al., “Effect of Potent and Selective Inhibitors of the Grb2 SH2 Domain on Cell Motility”, The Journal of Biological Chemistry, vol. 274, pp. 23311-23315, Aug. 13, 1999.
Schoepfer et al., “Highly Potent Inhibitors of the Grb2-SH2 Domain”, Bioorganic & Medicinal Chemistry Letters 9, pp. 211-226, 1999.
Burke, Jr., et al., Monocarboxylic-Based Phosphotyrosyl Mimetics in the Design of Grb2 SH2 Domain Inhibitors, Bioorganic & Medicinal Chemistry Letters 9, pp. 347-352, 1999.
Gilmer et al., “Peptide Inhibitors of src SH3-SH2-Phosphorprotein Interactions”, The Journal of Biological Chemistry, vol. 269, pp. 31711-31719, Dec. 16, 1994.
Charifson et al., “Peptide Ligands of pp60c-srcSH2 Domains: A Thermodynamic and Structural Study”, Biochemistry, vol. 36, pp. 6283-6293, 1997.
Liu et al., “Synthesis of L-2,3,5,6-Tetrafluoro-4-(Phosphonomethyl) Phenylalanine, a Novel Non-Hydrolyzable Phosphotyrosine Mimetic and L-4-(Phosphonodifluoromethyl)Phenylalanine”, Tetrahedron Letters, vol. 38, pp. 1389-1392, 1997.
Cleland, “The Meerwein Reaction in Amino Acid Synthesis. II. An Investigation of Twenty-one Substituted Anilines”, The Journal of Organic Chemistry, Vo., 34, pp. 744-747, Mar. 1969.
Gao et al., Inhibition of Grb2 SH2 Domain Binding by Non-Phosphate-Containing Ligands. 2. 4-(2-Malonyl)phenylalamine as a Potent Phosphotyrosyl Mimetic, J. Med. Chem., vol. 43, pp. 911-920, 2000.
Furet et al., Structure-Based Design and Synthesis of High Affinity Tripeptide Ligands of the Grb2-SH2 Domain, J. Med. Chem., vol. 41, pp. 3442-3449, 1998.
Tong et al., “Carboxymethyl-phenylalanine as a Replacement for Phosphotyrosine in SH2 Domain Binding”, The Journal of Biological Chemistry, vol. 273, pp. 20238-20242 Aug. 7, 1998.
Kim et al.,FEBS Lett, 453, 174-178, 1999.
Tulasne et al., “The Multisubstrate Docketing Site of the MET Receptor is Dispensable for MET-mediated RAS Signaling and Cell Scattering”, Molecular Biology of the Cell, vol. 10, pp. 551-565, Mar. 1999.
Kim et al., “Dual Signaling Role of the Prot
Atabey Safiye N.
Bottaro Donald P.
Breckenridge Diane E.
Burke, Jr. Terrence R.
Gao Yang
Campell Bruce R.
Kosar Andrew D.
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
Inhibition of cell motility and angiogenesis by inhibitors... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of cell motility and angiogenesis by inhibitors..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of cell motility and angiogenesis by inhibitors... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3693757